newsfilter
← Latest News
Business Wire·

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for